Theseus Pharmaceuticals, Inc.
THRX
Cena:
Valuace
70
Růst
0
Zdraví
75
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
THESEUS PHARMACEUTICALS ANNOUNCES CLOSING OF TENDER OFFER
14-02-2024
-- THESEUS STOCKHOLDERS TO RECEIVE $4.05 PER SHARE IN CASH PLUS CONTINGENT VALUE RIGHT -- CAMBRIDGE,...
Více zde
THESEUS PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF THESEUS PHARMACEUTICALS, INC. - THRX
22-01-2024
NEW ORLEANS , JAN. 22, 2024 /PRNEWSWIRE/ -- FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR...
Více zde
THESEUS PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF THESEUS PHARMACEUTICALS, INC. - THRX
31-12-2023
NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND TH...
Více zde
SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER THESEUS PHARMACEUTICALS, INC. HAS OBTAINED A FAIR PRICE IN ITS TRANSACTION WITH CONCENTRA
22-12-2023
MILWAUKEE , DEC. 22, 2023 /PRNEWSWIRE/ -- ADEMI LLP IS INVESTIGATING THESEUS (NASDAQ: THRX) FOR POSS...
Více zde
THRX STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF THESEUS PHARMACEUTICALS, INC. IS FAIR TO SHAREHOLDERS
22-12-2023
NEW YORK--(BUSINESS WIRE)--HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING WHETHER T...
Více zde
THESEUS PHARMACEUTICALS ENTERS INTO AGREEMENT TO BE ACQUIRED BY CONCENTRA BIOSCIENCES FOR BETWEEN $3.90 AND $4.05 IN CASH PER SHARE PLUS A CONTINGENT VALUE RIGHT
22-12-2023
CAMBRIDGE, MASS. , DEC. 22, 2023 /PRNEWSWIRE/ -- THESEUS PHARMACEUTICALS, INC. (NASDAQ: THRX) ("THES...
Více zde
THESEUS PHARMACEUTICALS CONFIRMS RECEIPT OF UNSOLICITED EXPRESSION OF INTEREST FROM FORESITE CAPITAL, LLC AND ORBIMED ADVISORS LLC AND UNSOLICITED PROPOSAL FROM CONCENTRA BIOSCIENCES LLC
27-11-2023
CAMBRIDGE, MASS. , NOV. 27, 2023 /PRNEWSWIRE/ -- ON NOVEMBER 22, 2023, THE BOARD OF DIRECTORS (THE B...
Více zde
THESEUS PHARMACEUTICALS ANNOUNCES BUSINESS HIGHLIGHTS AND REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS
10-08-2023
IND SUBMISSION FOR THE-349 IN EGFR-MUTANT NSCLC EXPECTED IN Q4 2023 DEVELOPMENT CANDIDATE NOMINATION...
Více zde
THESEUS PHARMACEUTICALS TO DISCONTINUE ENROLLMENT IN PHASE 1/2 STUDY AND TERMINATE DEVELOPMENT OF THE-630 IN PATIENTS WITH GIST
13-07-2023
-- DECISION FOLLOWS TWO DOSE-LIMITING TOXICITIES RELATED TO HAND-FOOT SKIN REACTION OBSERVED IN COHO...
Více zde
THESEUS PHARMACEUTICALS TO PARTICIPATE IN THE JEFFERIES HEALTHCARE CONFERENCE
31-05-2023
CAMBRIDGE, MASS. , MAY 31, 2023 /PRNEWSWIRE/ -- THESEUS PHARMACEUTICALS, INC. (NASDAQ: THRX) ("THESE...
Více zde
THESEUS PHARMACEUTICALS REPORTS INITIAL DOSE ESCALATION DATA FROM ONGOING PHASE 1/2 TRIAL OF THE-630 IN PATIENTS WITH ADVANCED GIST
25-05-2023
-- THE-630 DEMONSTRATES ENCOURAGING SAFETY PROFILE THROUGH COHORT 6 (18 MG), SUPPORTIVE OF CONTINUED...
Více zde
THESEUS PHARMACEUTICALS INITIAL DOSE ESCALATION RESULTS FROM ONGOING PHASE 1/2 TRIAL OF THE-630 ACCEPTED FOR ONLINE PUBLICATION AT 2023 ASCO ANNUAL MEETING
26-04-2023
-- COMPANY TO HOST VIRTUAL INVESTOR EVENT TO REVIEW UPDATED DATA ON MAY 25, 2023 AT 5:30PM ET -- CAM...
Více zde
THESEUS PHARMACEUTICALS TO PARTICIPATE IN THE CANTOR FUTURE OF ONCOLOGY VIRTUAL SYMPOSIUM
28-03-2023
CAMBRIDGE, MASS. , MARCH 28, 2023 /PRNEWSWIRE/ -- THESEUS PHARMACEUTICALS, INC. (NASDAQ: THRX) ("THE...
Více zde
THESEUS PHARMACEUTICALS ANNOUNCES BUSINESS HIGHLIGHTS AND REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
09-03-2023
THE-630 PHASE 1 PRELIMINARY DOSE-ESCALATION DATA ANTICIPATED IN Q2 2023; ADDITIONAL DATA INCLUDING D...
Více zde
THESEUS PHARMACEUTICALS TO PARTICIPATE IN THE SVB SECURITIES GLOBAL BIOPHARMA CONFERENCE
07-02-2023
CAMBRIDGE, MASS. , FEB. 7, 2023 /PRNEWSWIRE/ -- THESEUS PHARMACEUTICALS, INC. (NASDAQ: THRX) ("THESE...
Více zde
THESEUS PHARMACEUTICALS HIGHLIGHTS KEY ANTICIPATED 2023 MILESTONES AND ANNOUNCES BCR-ABL AS TARGET FOR THIRD DEVELOPMENT PROGRAM
05-01-2023
PROGRESSING PHASE 1/2 CLINICAL TRIAL OF THE-630 IN ADVANCED GIST; PRELIMINARY DOSE-ESCALATION DATA A...
Více zde
THESEUS PHARMACEUTICALS PRESENTS PRECLINICAL DATA CHARACTERIZING THE-349, ITS FOURTH-GENERATION EGFR INHIBITOR IN DEVELOPMENT FOR NSCLC, AT THE 34TH EORTC-NCI-AACR SYMPOSIUM
26-10-2022
POTENT SINGLE-MOLECULE INHIBITION OF ALL MAJOR CLASSES OF EGFR ACTIVATING AND RESISTANCE MUTATIONS, ...
Více zde
THESEUS PHARMACEUTICALS APPOINTS STEVEN STEIN, M.D. TO BOARD OF DIRECTORS
19-10-2022
CAMBRIDGE, MASS. , OCT. 19, 2022 /PRNEWSWIRE/ -- THESEUS PHARMACEUTICALS, INC. (NASDAQ: THRX) (THESE...
Více zde
THESEUS PHARMACEUTICALS NOMINATES THE-349, A FOURTH-GENERATION EGFR INHIBITOR DEVELOPMENT CANDIDATE IN NON-SMALL CELL LUNG CANCER
03-10-2022
THE-349 IS A FOURTH-GENERATION, POTENT AND SELECTIVE, SMALL MOLECULE DESIGNED TO INHIBIT ALL MAJOR C...
Více zde
THESEUS PHARMACEUTICALS TO PARTICIPATE VIRTUALLY IN WEDBUSH PACGROW HEALTHCARE CONFERENCE
03-08-2022
CAMBRIDGE, MASS. , AUG. 3, 2022 /PRNEWSWIRE/ -- THESEUS PHARMACEUTICALS, INC. (NASDAQ: THRX) (THESEU...
Více zde
THESEUS PHARMACEUTICALS APPOINTS DON HAYDEN TO BOARD OF DIRECTORS
18-05-2022
CAMBRIDGE, MASS. , MAY 18, 2022 /PRNEWSWIRE/ -- THESEUS PHARMACEUTICALS, INC. (NASDAQ: THRX) (THESEU...
Více zde
THESEUS PHARMACEUTICALS ANNOUNCES BUSINESS HIGHLIGHTS AND REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS
12-05-2022
THE-630 PHASE 1/2 CLINICAL TRIAL ACTIVELY ENROLLING PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL ...
Více zde
THESEUS PHARMACEUTICALS TO PARTICIPATE VIRTUALLY IN NEEDHAM HEALTHCARE CONFERENCE
05-04-2022
CAMBRIDGE, MASS. , APRIL 5, 2022 /PRNEWSWIRE/ -- THESEUS PHARMACEUTICALS, INC. (NASDAQ: THRX) ("THES...
Více zde
THESEUS PHARMACEUTICALS ANNOUNCES BUSINESS HIGHLIGHTS AND REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS
10-03-2022
CAMBRIDGE, MASS., MARCH 10, 2022 /PRNEWSWIRE/ -- THESEUS PHARMACEUTICALS, INC. (NASDAQ: THRX) (THES...
Více zde
THESEUS PHARMACEUTICALS TO PRESENT PRECLINICAL DATA CHARACTERIZING NEXT-GENERATION EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS AT THE 2022 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING
08-03-2022
CAMBRIDGE, MASS., MARCH 8, 2022 /PRNEWSWIRE/ -- THESEUS PHARMACEUTICALS, INC. (NASDAQ: THRX) (THESE...
Více zde
THESEUS PHARMACEUTICALS TO PARTICIPATE VIRTUALLY IN SVB LEERINK GLOBAL HEALTHCARE CONFERENCE
09-02-2022
CAMBRIDGE, MASS., FEB. 9, 2022 /PRNEWSWIRE/ -- THESEUS PHARMACEUTICALS, INC. (NASDAQ: THRX) ("THESEU...
Více zde
THESEUS PHARMACEUTICALS RECEIVES U.S. FDA ORPHAN DRUG DESIGNATION FOR THE-630 FOR THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST)
02-02-2022
CAMBRIDGE, MASS., FEB. 2, 2022 /PRNEWSWIRE/ -- THESEUS PHARMACEUTICALS, INC. (THESEUS) (NASDAQ: THRX...
Více zde
| Datum | Typ | Otevřít EDGAR | Stáhnout dokument |
|---|---|---|---|
| 2024-02-14 00:00:00 | 8-K |  | Stáhnout |
| 2024-02-13 23:00:00 | 8-K | | Stáhnout |
| 2023-12-22 00:00:00 | 8-K | | Stáhnout |
| 2023-12-21 23:00:00 | 8-K | | Stáhnout |
| 2023-12-04 00:00:00 | 8-K | | Stáhnout |
| 2023-12-03 23:00:00 | 8-K | | Stáhnout |
| 2023-11-27 00:00:00 | 8-K | | Stáhnout |
| 2023-11-26 23:00:00 | 8-K | | Stáhnout |
| 2023-11-17 00:00:00 | 10-Q | | Stáhnout |
| 2023-11-16 23:00:00 | 10-Q | | Stáhnout |
| 2023-11-13 00:00:00 | 8-K | | Stáhnout |
| 2023-11-12 23:00:00 | 8-K | | Stáhnout |
| 2023-10-31 00:00:00 | 8-K | | Stáhnout |
| 2023-10-30 23:00:00 | 8-K | | Stáhnout |
| 2023-08-10 01:00:00 | 8-K | | Stáhnout |
| 2023-08-10 01:00:00 | 10-Q | | Stáhnout |
| 2023-08-10 00:00:00 | 8-K | | Stáhnout |
| 2023-08-10 00:00:00 | 10-Q | | Stáhnout |
| 2023-07-13 01:00:00 | 8-K | | Stáhnout |
| 2023-07-13 00:00:00 | 8-K | | Stáhnout |
| 2023-06-09 01:00:00 | 8-K | | Stáhnout |
| 2023-06-09 00:00:00 | 8-K | | Stáhnout |
| 2023-05-25 01:00:00 | 8-K | | Stáhnout |
| 2023-05-25 00:00:00 | 8-K | | Stáhnout |
| 2023-05-11 01:00:00 | 8-K | | Stáhnout |
| 2023-05-11 01:00:00 | 10-Q | | Stáhnout |
| 2023-05-11 00:00:00 | 8-K | | Stáhnout |
| 2023-05-11 00:00:00 | 10-Q | | Stáhnout |
| 2023-03-09 00:00:00 | 8-K | | Stáhnout |
| 2023-03-09 00:00:00 | 10-K | | Stáhnout |
| 2023-03-08 23:00:00 | 8-K | | Stáhnout |
| 2023-03-08 23:00:00 | 10-K | | Stáhnout |
| 2023-01-05 00:00:00 | 8-K | | Stáhnout |
| 2023-01-04 23:00:00 | 8-K | | Stáhnout |
| 2022-11-03 00:00:00 | 8-K | | Stáhnout |
| 2022-11-03 00:00:00 | 10-Q | | Stáhnout |
| 2022-11-02 23:00:00 | 8-K | | Stáhnout |
| 2022-11-02 23:00:00 | 10-Q | | Stáhnout |
| 2022-10-19 01:00:00 | 8-K | | Stáhnout |
| 2022-10-19 00:00:00 | 8-K | | Stáhnout |
| 2022-08-11 01:00:00 | 8-K | | Stáhnout |
| 2022-08-11 01:00:00 | 10-Q | | Stáhnout |
| 2022-08-11 00:00:00 | 8-K | | Stáhnout |
| 2022-08-11 00:00:00 | 10-Q | | Stáhnout |
| 2022-06-13 01:00:00 | 8-K | | Stáhnout |
| 2022-06-13 00:00:00 | 8-K | | Stáhnout |
| 2022-05-18 01:00:00 | 8-K | | Stáhnout |
| 2022-05-18 00:00:00 | 8-K | | Stáhnout |
| 2022-05-12 01:00:00 | 8-K | | Stáhnout |
| 2022-05-12 01:00:00 | 10-Q | | Stáhnout |
| 2022-05-12 00:00:00 | 8-K | | Stáhnout |
| 2022-05-12 00:00:00 | 10-Q | | Stáhnout |
| 2022-03-10 00:00:00 | 8-K | | Stáhnout |
| 2022-03-10 00:00:00 | 10-K | | Stáhnout |
| 2022-03-09 23:00:00 | 8-K | | Stáhnout |
| 2022-03-09 23:00:00 | 10-K | | Stáhnout |
| 2022-01-10 00:00:00 | 8-K | | Stáhnout |
| 2022-01-09 23:00:00 | 8-K | | Stáhnout |
| 2021-11-15 00:00:00 | 8-K | | Stáhnout |
| 2021-11-15 00:00:00 | 10-Q | | Stáhnout |
| 2021-11-14 23:00:00 | 8-K | | Stáhnout |
| 2021-11-14 23:00:00 | 10-Q | | Stáhnout |
| 2021-10-27 01:00:00 | 8-K | | Stáhnout |
| 2021-10-27 00:00:00 | 8-K | | Stáhnout |
